CD55-deficient Protein-losing EnteropathyNCT05232110
Compassionate Use of Pozelimab
A study testing Pozelimab in people with CD55-deficient Protein-losing Enteropathy, run by Regeneron Pharmaceuticals.
Trial summary
Provide compassionate use of pozelimab Read more about this study
- Who is it for?
- Any age
- Conditions the study is for
- CD55-deficient Protein-losing Enteropathy
- What is being tested?
- Pozelimab
- How many people
- Not given
- Where
- No sites listed yet
- Study dates
- Start not givento not given
- Phase
- Expanded access
- Are there results?
- None posted in the registry
Key requirements
Who can take part, as listed by the sponsor. Only the study team can confirm whether you are eligible, so take this list to your doctor.
- Ages Any age
- Child, Adult, Older adult
Who may be able to join
- -
Who cannot join
- -
About this study
Provide compassionate use of pozelimab
Read the detailed description
Compassionate Use requests are only being considered in response to Individual Patient Investigational New Drug (IND) applications.
- Being tested
- Pozelimab
- Keywords
- Complement Hyperactivation, Angiopathic thrombosis, Protein-Losing Enteropathy (CHAPLE disease)
- Medical subject headings
- Protein-Losing Enteropathies
What participants receive
What participants receive. In a randomised study each person is assigned to one group by chance.
PozelimabDrug
Also called REGN3918
Timeline
From the start of the study to its completion; the mark is today. Estimated dates are the sponsor’s plan.
- First posted9 Feb 2022
Resources
- Official record on ClinicalTrials.govThe registry entry this page is built from, with its full change history.
- Other trials for CD55-deficient Protein-losing EnteropathyStudies of the same condition, open and under way.
- More trials run by Regeneron PharmaceuticalsThe sponsor's other registered studies.
- What the trial phases meanHow a treatment moves from first tests in people to approval.
More details
For doctors and researchers: how the study is designed, who runs it, and its registry IDs.
Study design
- Study type
- Expanded access
Sponsor and investigators
- Lead sponsor
- Regeneron Pharmaceuticals
- Sponsor type
- Industry (pharma, biotech, devices)
- Responsible party
- Sponsor
IDs, dates and publications
- ClinicalTrials.gov ID
- NCT05232110
- Sponsor's protocol ID
- R3918-Pozelimab
- Status last verified
- Nov 2025
- First submitted
- 28 Jan 2022
- Last updated
- 10 Nov 2025
- Results posted
- No
Study at a glance
From the registry record, last updated by the sponsor on 10 Nov 2025. Recruitment status is as the sponsor reported it: confirm with the study team.
- Official title
- Compassionate Use of Pozelimab
- ClinicalTrials.gov ID
- NCT05232110
- Acronym / sponsor ID
- R3918-Pozelimab
- Keywords
- Complement Hyperactivation, Angiopathic thrombosis, Protein-Losing Enteropathy (CHAPLE disease)
- Study type
- Expanded access
- Recruitment status
- Approved For Marketing
- Lead sponsor
- Regeneron PharmaceuticalsIndustry (pharma, biotech, devices)
- First posted
- 9 Feb 2022 (actual)
- Results
- Not posted in the source record
Clinical summary
The research question as the sponsor registered it. This describes what the study plans to test, not what it found.
Provide compassionate use of pozelimab
Detailed description
Compassionate Use requests are only being considered in response to Individual Patient Investigational New Drug (IND) applications.
Study design
Who may qualify
- Age groups
- Child, Adult, Older adult
Key inclusion criteria (1 listed)
- -
Key exclusion criteria (1 listed)
- -
Eligibility is decided by the study team after screening; this overview does not establish that a patient qualifies. Full inclusion and exclusion criteria.
Interventions
| Intervention | Type | Arms |
|---|---|---|
| PozelimabAlso: REGN3918 | Drug | – |
Primary outcome
Not reported in the source record.
Results and safety
Results are not available in the source record.
Research links
- Official record on ClinicalTrials.govLast updated by the sponsor 10 Nov 2025.
Related trials for CD55-deficient Protein-losing Enteropathy
Referral and contact
AzTrials does not enrol participants or take referrals. Contact the study team or a site listed below; they decide who can take part. This study is not recruiting at the moment.
The record lists no contact. Use the official record to reach the sponsor.
Questions about this trial
What is this clinical trial studying?
A study testing Pozelimab in people with CD55-deficient Protein-losing Enteropathy, run by Regeneron Pharmaceuticals.
The full registered description is in the About this study section and the official record.
Who may be eligible to take part?
The sponsor lists 1 inclusion and 1 exclusion criteria. Eligibility is decided by the study team after screening, so read the full criteria and contact a listed site.
Is this clinical trial currently recruiting?
The record says: status not confirmed, as of the sponsor's last update on 10 Nov 2025. Status can change between updates, so confirm with the study contact before making plans.
What are the possible benefits and risks?
They depend on the study and the treatment, and no study can promise a benefit. The study team explains the known risks during informed consent, before anyone joins; the record itself does not list them.
Are results available for this study?
Results are not available in the source record.
How can a doctor refer a patient or contact the research team?
The record lists no contact. The official record names the sponsor, who can be asked directly. AzTrials does not enrol participants or take referrals.
Where can I read the original study information?
Does a listing mean the treatment is approved or proven to work?
No. A listing means the study is registered. It does not show that the treatment is safe, works, or is approved by a regulator.
How often is this information updated?
AzTrials copies changed records from ClinicalTrials.gov every night and reloads the whole registry every week. The sponsor last updated this record on 10 Nov 2025.